Clinical Advances in Interstitial Lung Diseases
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Pulmonary".
Deadline for manuscript submissions: 20 May 2024 | Viewed by 145
Special Issue Editors
Interests: interstitial lung diseases; pulmonary medicine; diffuse lung disease; lung diseases; pulmonary fibrosis; tuberculosis
Special Issues, Collections and Topics in MDPI journals
Interests: respirology; diffuse lung disease
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The field of interstitial lung disease has experienced significant progress over the past decade. The cryobiopsy method has been established as a method for obtaining tissue samples for the pathology. With the improvement of analysis technology using artificial intelligence, there have also been remarkable developments in genome classification. In pharmacological therapy, two antifibrotic agents, pirfenidone and nintedanib, have provided alternatives to conventional corticosteroid-based anti-inflammatory therapy and are effective in the treatment of idiopathic and progressive pulmonary fibrosis. Additionally, today, many compounds with antifibrotic activity are in development. Scientific evidence is also slowly but surely establishing non-pharmacological therapies, such as respiratory rehabilitation. We now need to understand the pathophysiology and prognoses of patients with interstitial lung disease and provide appropriate treatment and management.
In this Special Issue, we welcome authors to submit papers that will provide more reliable evidence of the advances in the diagnosis and treatment of interstitial lung disease.
You may choose our Joint Special Issue in Journal of Clinical Medicine.
Dr. Yoshiaki Zaizen
Dr. Masaki Okamoto
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- interstitial lung disease
- idiopathic interstitial pneumonias
- idiopathic pulmonary fibrosis
- hypersensitivity pneumonitis
- connective tissue disease-associated interstitial lung disease
- diagnosis
- treatment
